KR20180095140A - α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH - Google Patents

α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH Download PDF

Info

Publication number
KR20180095140A
KR20180095140A KR1020187023820A KR20187023820A KR20180095140A KR 20180095140 A KR20180095140 A KR 20180095140A KR 1020187023820 A KR1020187023820 A KR 1020187023820A KR 20187023820 A KR20187023820 A KR 20187023820A KR 20180095140 A KR20180095140 A KR 20180095140A
Authority
KR
South Korea
Prior art keywords
sialylation
fsh
rfsh
recombinant fsh
total
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187023820A
Other languages
English (en)
Korean (ko)
Inventor
이안 코팅햄
다니엘 플락신
리차드 보이드 화이트
Original Assignee
페링 인터내셔널 센터 에스 에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20180095140(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 페링 인터내셔널 센터 에스 에이 filed Critical 페링 인터내셔널 센터 에스 에이
Publication of KR20180095140A publication Critical patent/KR20180095140A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1081Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020187023820A 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH Ceased KR20180095140A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
US61/045,424 2008-04-16
EP08251528 2008-04-25
EP08251528.9 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026920A Division KR20170110741A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197022294A Division KR102108377B1 (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH

Publications (1)

Publication Number Publication Date
KR20180095140A true KR20180095140A (ko) 2018-08-24

Family

ID=39717519

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020187023820A Ceased KR20180095140A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020177026920A Ceased KR20170110741A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020107025581A Active KR101622944B1 (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020197022294A Active KR102108377B1 (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020167012148A Ceased KR20160056960A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020177026920A Ceased KR20170110741A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020107025581A Active KR101622944B1 (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020197022294A Active KR102108377B1 (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020167012148A Ceased KR20160056960A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH

Country Status (29)

Country Link
US (5) US8951967B2 (cg-RX-API-DMAC7.html)
EP (7) EP3098234B1 (cg-RX-API-DMAC7.html)
JP (7) JP2011519359A (cg-RX-API-DMAC7.html)
KR (5) KR20180095140A (cg-RX-API-DMAC7.html)
CN (3) CN105906703A (cg-RX-API-DMAC7.html)
AR (1) AR071479A1 (cg-RX-API-DMAC7.html)
AU (5) AU2009237479B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910461B8 (cg-RX-API-DMAC7.html)
CA (1) CA2725257A1 (cg-RX-API-DMAC7.html)
CY (1) CY1115413T1 (cg-RX-API-DMAC7.html)
DK (6) DK4015527T3 (cg-RX-API-DMAC7.html)
ES (5) ES2989729T3 (cg-RX-API-DMAC7.html)
FI (4) FI3098234T3 (cg-RX-API-DMAC7.html)
FR (3) FR17C1020I2 (cg-RX-API-DMAC7.html)
HR (5) HRP20241187T1 (cg-RX-API-DMAC7.html)
HU (9) HUE071059T2 (cg-RX-API-DMAC7.html)
IL (2) IL208538A (cg-RX-API-DMAC7.html)
LT (8) LT2808340T (cg-RX-API-DMAC7.html)
MX (3) MX355457B (cg-RX-API-DMAC7.html)
NO (4) NO2017025I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ588381A (cg-RX-API-DMAC7.html)
PL (6) PL2268666T3 (cg-RX-API-DMAC7.html)
PT (6) PT3098234T (cg-RX-API-DMAC7.html)
RU (3) RU2682270C2 (cg-RX-API-DMAC7.html)
SA (1) SA109300228B1 (cg-RX-API-DMAC7.html)
SI (6) SI3098234T1 (cg-RX-API-DMAC7.html)
TW (1) TWI488640B (cg-RX-API-DMAC7.html)
WO (1) WO2009127826A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007373B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
DK2621517T4 (da) 2010-09-29 2023-11-20 Ferring Bv Sammensætning til anvendelse i behandlingen af infertilitet
JP5918697B2 (ja) 2010-10-15 2016-05-18 Jcrファーマ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
ES2693273T3 (es) * 2011-03-31 2018-12-10 Ferring B.V. Preparación farmacéutica
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
US9657310B2 (en) * 2012-04-27 2017-05-23 Jcr Pharmaceuticals Co., Ltd. Expression vector
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Jcrファーマ株式会社 ウリジンとn−アセチル−d−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cmp依存性シアリダーゼ活性
HUE054300T2 (hu) 2015-04-17 2021-08-30 Ferring Bv FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény
WO2016207353A1 (en) 2015-06-26 2016-12-29 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
DK3973982T3 (da) 2017-09-01 2024-09-23 Ferring Bv Sammensætning til kontrolleret ovariestimulation
HUE071268T2 (hu) 2018-04-30 2025-08-28 Ferring Bv Készítmény szabályozott petefészek-stimuláláshoz
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
AU2022451605A1 (en) 2022-04-01 2024-09-26 Ferring B.V. Mixed protocol for treatment of infertility
CA3255772A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods of treating infertility in men
KR20250033230A (ko) 2022-07-08 2025-03-07 훼링 비.브이. 자궁내 인공수정(iui)을 위한 조성물 및 방법
AR133300A1 (es) 2023-07-20 2025-09-17 Ferring Bv Micropartículas cargadas con fármaco de liberación prolongada

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
ATE263841T1 (de) 1997-01-16 2004-04-15 Neose Technologies Inc Praktische in vitro sialylierung von rekombinanten glykpproteinen
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
CA2372714A1 (en) 1999-05-07 2000-11-16 Stephen Franks The use of luteinizing hormone in the induction of pauci-or unifolliculogenesis
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
UA87433C2 (ru) * 2001-10-22 2009-07-27 Еплайд Рісьорч Системз Ерс Холдінг Н.В. Гонадотропины для стимулирования фолликулогенеза
ES2381104T3 (es) 2001-10-29 2012-05-23 Crucell Holland B.V. Métodos y medios para producir proteínas con modificaciones postraduccionales predeterminadas
CN100547069C (zh) 2001-12-07 2009-10-07 克鲁塞尔荷兰公司 病毒、病毒分离物和疫苗的生产
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
ATE476666T1 (de) 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
CN1926242B (zh) * 2004-02-13 2013-01-16 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
DK2621517T4 (da) 2010-09-29 2023-11-20 Ferring Bv Sammensætning til anvendelse i behandlingen af infertilitet
ES2693273T3 (es) 2011-03-31 2018-12-10 Ferring B.V. Preparación farmacéutica
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2015248793A1 (en) 2014-04-18 2016-11-03 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
LTPA2025525I1 (cg-RX-API-DMAC7.html) 2025-07-25
LTPA2017029I1 (lt) 2017-10-10
PT3098234T (pt) 2024-10-21
FI4015527T3 (fi) 2025-04-29
KR20170110741A (ko) 2017-10-11
NO2025032I1 (no) 2025-07-14
AU2017225020A1 (en) 2017-09-28
KR20190092608A (ko) 2019-08-07
BRPI0910461B8 (pt) 2021-05-25
PT3144318T (pt) 2020-11-04
EP2268666A1 (en) 2011-01-05
SA109300228B1 (ar) 2014-04-08
EP4015527B1 (en) 2025-01-22
PL3045471T3 (pl) 2017-10-31
NZ588381A (en) 2012-05-25
SI2808340T1 (sl) 2016-12-30
KR20160056960A (ko) 2016-05-20
US9771407B2 (en) 2017-09-26
AU2014203277A1 (en) 2014-07-24
LT3098234T (lt) 2024-09-10
JP2011519359A (ja) 2011-07-07
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
FIC20250025I1 (fi) 2025-07-11
MX355457B (es) 2018-04-19
DK4015527T3 (da) 2025-04-14
ES3023526T3 (en) 2025-06-02
HK1199039A1 (en) 2015-06-19
US20240327487A1 (en) 2024-10-03
DK2268666T3 (da) 2014-05-12
HK1146284A1 (en) 2011-05-20
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
US8951967B2 (en) 2015-02-10
US20180079794A1 (en) 2018-03-22
HUE030652T2 (en) 2017-05-29
JP2024038000A (ja) 2024-03-19
LT4015527T (lt) 2025-04-10
SI4015527T1 (sl) 2025-05-30
JP2022031652A (ja) 2022-02-22
US20110105398A1 (en) 2011-05-05
EP3144318B1 (en) 2020-09-23
HRP20161520T1 (hr) 2016-12-30
IL208538A0 (en) 2010-12-30
RU2014141994A3 (cg-RX-API-DMAC7.html) 2018-05-28
FR25C1003I1 (fr) 2025-02-28
SI3045471T1 (sl) 2017-07-31
US20150065695A1 (en) 2015-03-05
RU2745557C3 (ru) 2021-12-10
ES2989729T3 (es) 2024-11-27
NO2017050I1 (no) 2017-09-28
HUS2500029I1 (hu) 2025-07-28
FI3098234T3 (fi) 2024-10-31
RU2745557C1 (ru) 2021-03-29
EP2808340A1 (en) 2014-12-03
LTPA2017018I1 (lt) 2017-06-26
LT3045471T (lt) 2017-07-10
TW200948378A (en) 2009-12-01
IL230571A (en) 2015-11-30
PT2268666E (pt) 2014-06-25
HUE068565T2 (hu) 2025-01-28
PT3045471T (pt) 2017-06-14
LT2808340T (lt) 2016-11-10
US9546204B2 (en) 2017-01-17
ES2468318T3 (es) 2014-06-16
RU2537268C2 (ru) 2014-12-27
CN102066414A (zh) 2011-05-18
MX348622B (es) 2017-06-22
JP6762916B2 (ja) 2020-09-30
SI3144318T1 (sl) 2020-12-31
PT4015527T (pt) 2025-04-10
EP2268666B1 (en) 2014-03-12
HUS1700036I1 (hu) 2017-10-30
FIC20250003I1 (fi) 2025-01-15
TWI488640B (zh) 2015-06-21
AU2009237479A1 (en) 2009-10-22
FR17C1020I1 (cg-RX-API-DMAC7.html) 2020-04-10
HUE033830T2 (en) 2018-01-29
RU2682270C2 (ru) 2019-03-18
HUS2500008I1 (hu) 2025-02-28
US11952407B2 (en) 2024-04-09
JP2015120696A (ja) 2015-07-02
HUE030652T4 (en) 2017-09-28
BRPI0910461A8 (pt) 2018-10-16
KR20110005863A (ko) 2011-01-19
LTPA2025505I1 (cg-RX-API-DMAC7.html) 2025-02-10
EP3045471B1 (en) 2017-03-29
PT2808340T (pt) 2016-11-21
CN105906702A (zh) 2016-08-31
DK2808340T3 (en) 2016-12-05
FR17C1020I2 (fr) 2020-04-10
AU2017204259B2 (en) 2017-08-17
RU2014141994A (ru) 2016-05-10
US10995128B2 (en) 2021-05-04
JP6486310B2 (ja) 2019-03-20
HRP20241187T1 (hr) 2024-12-06
JP2018021037A (ja) 2018-02-08
HRP20250313T1 (hr) 2025-05-09
AU2009237479B2 (en) 2014-05-15
US20210332099A1 (en) 2021-10-28
JP7316905B2 (ja) 2023-07-28
AU2017204259A1 (en) 2017-07-20
ES2629392T3 (es) 2017-08-09
DK3144318T3 (da) 2020-12-07
PL2268666T3 (pl) 2014-08-29
AR071479A1 (es) 2010-06-23
CN105906703A (zh) 2016-08-31
SI3098234T1 (sl) 2024-10-30
CA2725257A1 (en) 2009-10-22
AU2017204258A1 (en) 2017-07-20
IL208538A (en) 2014-03-31
PL2808340T3 (pl) 2017-02-28
BRPI0910461A2 (pt) 2018-03-27
HUS1700025I1 (hu) 2017-06-28
KR102108377B1 (ko) 2020-05-08
US20160347811A1 (en) 2016-12-01
BRPI0910461B1 (pt) 2021-02-23
ZA201007373B (en) 2011-06-29
JP2020040956A (ja) 2020-03-19
CY1115413T1 (el) 2017-01-04
RU2010141908A (ru) 2012-05-27
PL3098234T3 (pl) 2025-01-07
NO2025006I1 (no) 2025-01-16
FR25C1025I1 (fr) 2025-09-19
EP2808340B1 (en) 2016-08-17
HUS1700024I1 (hu) 2017-06-28
EP3045471A1 (en) 2016-07-20
EP2722339A1 (en) 2014-04-23
HUE071059T2 (hu) 2025-07-28
KR101622944B1 (ko) 2016-05-23
EP3144318A1 (en) 2017-03-22
JP2017060476A (ja) 2017-03-30
DK3098234T3 (da) 2024-10-21
SI2268666T1 (sl) 2014-07-31
NO2017025I1 (no) 2017-06-06
DK3045471T3 (en) 2017-06-26
EP3098234B1 (en) 2024-07-31
EP3098234A1 (en) 2016-11-30
EP4015527A1 (en) 2022-06-22
AU2017204258B2 (en) 2017-08-17
AU2014203277C1 (en) 2017-07-27
AU2014203277B2 (en) 2017-04-06
PL3144318T3 (pl) 2021-02-08
AU2017225020B2 (en) 2019-11-14
HRP20170958T1 (hr) 2017-09-22
WO2009127826A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
JP7316905B2 (ja) アルファ2,3-およびアルファ2,6-シアリル化を含む組換えfsh
HK40068781B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1233276B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1227049B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1199039B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1227046B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1197825A (en) Recombinant fsh including alpha 2,3-and alpha 2,6-sialylation

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180817

Application number text: 1020177026920

Filing date: 20170922

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180914

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181204

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190429

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181204

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190729

Application number text: 1020177026920

Filing date: 20170922

PJ0201 Trial against decision of rejection

Patent event date: 20190729

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20190429

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190802

Appeal identifier: 2019101002538

Request date: 20190729

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20190802

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2019101002538

Request date: 20190729

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190802